Category
Diseases
Disease-area coverage across oncology, infectious disease, rare conditions, metabolic and cardiovascular disease and more — focused on the evidence, the treatments and the access questions in each.
542 articles in this topic.
Articles in this category
10/20/2026
Biomarker laboratory in Portugal opens at University of Porto
A new biomarker laboratory in Portugal opens on 21 October at the University of Porto, funded with 2.1 million euros from the PRR. #SyenzaNews #biomarkers #precisionmedicine
Read Article →
10/20/2026
Emvistegrast in ulcerative colitis hits Phase 2 primary endpoint
Gilead's once-daily oral emvistegrast met the primary endpoint in Phase 2 SWIFT ulcerative colitis data, with 66% clinical response at Week 12 versus 37% on placebo. #SyenzaNews #biotechnology #MarketAccess
Read Article →
10/20/2026
Jemperli rectal cancer approval may let some patients skip standard treatment
FDA grants accelerated approval for Jemperli in locally advanced rectal cancer, based on interim AZUR-1 results. #SyenzaNews #oncology #MarketAccess
Read Article →
10/19/2026
Adverse reaction reports in Portugal rise with GLP-1 use
Infarmed has logged 695 suspected adverse reactions to GLP-1 drugs in Portugal since 2024, most linked to Mounjaro.
Read Article →
10/19/2026
Foundayo Oral GLP-1 Tablet Gets Positive EU Opinion
The EMA's CHMP has backed Foundayo, a once-daily orforglipron tablet, for weight management and type 2 diabetes.
Read Article →
10/19/2026
Reinforcement learning rTMS for depression treatment
Reinforcement learning rTMS for depression: a new npj Digital Medicine study tests protocol recommendations against clinician choices in 1,609 adults.
Read Article →
10/15/2026
FDA Rare Disease Framework Initiative Would Tailor Review to Small Populations
What steps is the FDA taking to accelerate rare disease treatments?
The FDA’s new Rare Disease Framework Initiative aims to streamline regulatory pathways, enhance collaboration with sponsors, and improve patient access to innovative therapies.
Explore how this could reshape drug development for underserved patient populations.
#SyenzaNews #regulatoryaffairs #drugdevelopment #innovation #healthcarepolicy
Read Article →
10/15/2026
Semaglutide for Opioid Use Disorder: $13.3M Trial Planned in Allegheny County
Researchers and Allegheny County plan a $13.3 million trial of weekly semaglutide to reduce opioid and alcohol use and justice involvement.
Read Article →
10/15/2026
Social prescribing in Portugal: pilots, gaps and the cost of time
Social prescribing is not yet part of Portugal's national health system. Economists are asking whether it works, and who pays for it.
Read Article →
10/14/2026
BNT113 head and neck cancer trial misses first endpoint
BioNTech's AHEAD-MERIT trial did not reach significance on progression-free survival. The overall survival read-out is still to come.
Read Article →
10/14/2026
Rapid-Acting Insulin Analogue Cost-Effectiveness in Type 1 Diabetes: What the Evidence Shows
Insulin analogue cost-effectiveness studies for adults with type 1 diabetes mostly point the same way: the newer products usually come out ahead of human insulin. A new systematic review says that headline rests on thinner ground than it looks. The paper, by Shiwa Yaghoubi Bina, Steve Njokuocha and the T1D Economic Evidence Synthesis Group, has been accepted for Value in Health. The version available now is a pre-proof, so figures could still change at copyediting. The World Health Organization funded […]
Read Article →
10/14/2026
Denosumab Ascend Biosimilar Wins EU Authorisation for Bone Complications
The EMA has authorised Denosumab Ascend, a biosimilar of Xgeva. Here is what the assessment shows on safety, efficacy and use. #SyenzaNews #biotechnology #MarketAccess
Read Article →